Baillie Gifford & Co
YARW

Baillie Gifford & Co’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

Baillie Gifford & Co’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-110
Closed -$65K – 511
2022
Q1 		$65K Hold
110
– – ﹤0.01% 299
2021
Q4 		$101K Hold
110
– – ﹤0.01% 297
2021
Q3 		$138K Hold
110
– – ﹤0.01% 280
2021
Q2 		$347K Hold
110
– – ﹤0.01% 272
2021
Q1 		$676K Hold
110
– – ﹤0.01% 264
2020
Q4 		$624K Hold
110
– – ﹤0.01% 254
2020
Q3 		$655K Hold
110
– – ﹤0.01% 244
2020
Q2 		$683K Buy
110
+74
+206% +$501K ﹤0.01% 227
2020
Q1 		$349K Buy
+36
New +$565K ﹤0.01% 210

Other funds holding YARW

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

Baillie Gifford & Co's YARW Position: Q2 2022 in Review

Baillie Gifford & Co sold out of Yarrow Bioscience, Inc. Common Stock (YARW) in Q2 2022, closing a stake of 110 shares — an estimated $65K sold.

Baillie Gifford & Co first reported a position in YARW in Q1 2020 and held it in 9 quarters. The position peaked at $683K in Q2 2020. 37 funds tracked by Wall St. Rank hold YARW as of Q2 2022.

  • Baillie Gifford & Co reported no remaining Yarrow Bioscience, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Baillie Gifford & Co sold 110 Yarrow Bioscience, Inc. Common Stock shares in Q2 2022, an estimated $65K.
  • Baillie Gifford & Co first reported a position in Yarrow Bioscience, Inc. Common Stock in Q1 2020 and held it in 9 quarters.
  • Baillie Gifford & Co's Yarrow Bioscience, Inc. Common Stock position peaked at $683K in Q2 2020.
  • 37 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q2 2022.

Based on Baillie Gifford & Co's 13F filing for Q2 2022, filed 8 Aug 2022.